Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis.

To identify predictors of clinical disease activity after treatment change to higher-dose interferon beta-1a in relapsing-remitting multiple sclerosis (MS). This was a retrospective-prospective observational multicenter study. We enrolled patients with at least one relapse on platform injectable therapy who were changed to 44 μg interferon beta-1a.

Encephalitis with anti-NMDA receptor antibodies: paraneoplastic or non-paraneoplastic?

We report the case of an encephalitis patient with anti-N-methyl-D-aspartate receptor (NMDAR) antibody positivity. Anti-NMDAR encephalitis is a relatively rare autoimmune disease. In our patient, the diagnosis of anti-NMDAR encephalitis was established as late as several months after the first manifestations of the condition.

Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.

Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, which often causes progressive neurological disability. In addition to motor and sensory dysfunction, cognitive decline and fatigue are frequent manifestations of the disease. Fatigue is probably the most common symptom, with up to 90% of MS individuals reporting fatigue at some point.